| Literature DB >> 25642159 |
Elżbieta Kamysz1, Emilia Sikorska1, Małgorzata Dawgul2, Rafał Tyszkowski1, Wojciech Kamysz2.
Abstract
Lactoferrin (LF) is a naturally occurring antimicrobial peptide that is cleaved by pepsin to lactoferricin (LFcin). LFcin has an enhanced antimicrobial activity as compared to that of LF. Recently several hetero- and homodimeric antimicrobial peptides stabilized by a single disulfide bond linking linear polypeptide chains have been discovered. We have demonstrated that the S-S bond heterodimerization of lipopeptide Laur-Orn-Orn-Cys-NH2 (peptide III) and the synthetic N-terminal peptide of human lactoferricin (peptide I) yields a dimer (peptide V), which is almost as microbiologically active as the more active monomer and at the same time it is much less toxic. Furthermore, it has been found that the S-S bond homodimerization of both peptide I and peptide III did not affect antimicrobial and haemolytic activity of the compounds. The homo- and heterodimerization of peptides I and III resulted in either reduction or loss of antifungal activity. This work suggests that heterodimerization of antimicrobial lipopeptides via intermolecular disulfide bond might be a powerful modification deserving consideration in the design of antimicrobial peptides.Entities:
Keywords: Antimicrobial activity; Circular dichroism; Haemolytic activity; Lactoferricin; Lactoferrin; Lipopeptide
Year: 2014 PMID: 25642159 PMCID: PMC4305368 DOI: 10.1007/s10989-014-9423-y
Source DB: PubMed Journal: Int J Pept Res Ther ISSN: 1573-3149 Impact factor: 1.931
Fig. 1The primary structures of the peptides studied
Physicochemical characteristics of the peptides I–V
| Symbol | Formula | HPLC | calculated monoisotopic mass | [M + H]+ found |
|---|---|---|---|---|
| Peptide | C56H95N26O13S1 | 2.9 | 1,371.7 | 1,372.6 |
| Peptide | C112H188N26O13S1 | 4.3 | 2,741.4 | 2,742.4 |
| Peptide | C25H50N6O4S1 | 11.4 | 530.3 | 531.4 |
| Peptide | C50H98N12O8S2 | 9.6 | 1,058.6 | 1,059.4 |
| Peptide | C81H143N32O17S2 | 6.8 | 1,900.0 | 1,901.1 |
*linear gradient from 10–80 % of [B] for 20 min, Phenomenex Onyx Monolithic C18 column (100 × 4.6 mm) using a flow rate of 3 mL/min and with the following solvent systems: 0.1 % aqueous TFA [A], 0.1 % TFA in acetonitrile [B]
Antimicrobial activity of the peptides I–V
| Organism | Antimicrobial activity (µg/mL) | ||||
|---|---|---|---|---|---|
| Peptide | Peptide | Peptide | Peptide | Peptide | |
| Gram-positive bacteria | |||||
| | 256 | 256 | 2 | 4 | 32 |
| | 16 | 8 | 2 | 1 | 2 |
| | 64 | 64 | 2 | 2 | 4 |
| | 2 | 2 | 2 | 2 | 1 |
| | 2 | 1 | 4 | 2 | 2 |
| Gram-negative bacteria | |||||
| | 512 | 512 | 8 | 8 | 128 |
| | 32 | 32 | 8 | 4 | 8 |
| Fungi | |||||
| | 128 | 256 | 128 | >512 | >512 |
Haemolytic activity (µg/mL) of the peptides I–V
| Cells | Peptide | Peptide | Peptide | Peptide | Peptide |
|---|---|---|---|---|---|
| Human red blood cells | >512 | >512 | 16 | 16 | 128 |
Fig. 2CD spectra (left panel) and CD data analysis via the CONTINLL algorithm (right panel) of the peptides studied under different experimental conditions